Filtered by tag "Medical Marijuana"

What Proposed Tax Cuts Mean for Cannabis: Only a Bill?

By Selvan Boominathan, JD, LLM What We Learned:  A December 2017 review of the proposed Republican tax cuts suggested how politicians would not touch 280E, but still help the legal cannabis industry. In a prior post, we discussed how federal income tax applies to cannabis businesses and the huge burden imposed by Section 280E.  You […]
Read more

Cost Segregation and Benefits for Real Estate Investors

What We Learned: Operators owning property types which have a tax basis of at least $1 million, and that are subject to depreciation, can qualify for a cost segregation study (CSS). By Derek Weaver, Senior Manager As discussed in December 2017, 280E continues to be a major problem for plant-touching businesses. However, there are several […]
Read more

Alaska Debates Whether to Allow Onsite Consumption

By J.J. McCoy, Senior Managing Editor for New Frontier Data What We Learned: Especially with Alaska’s indoor culture, the popularity of social clubs would seem promising. Were Santa to try and find some medical cannabis to help treat his lower back after completion of his Christmas rounds, a dispensary in Denali, Alaska, would be the closest […]
Read more

Hemp & CBD: Expo West 2018 Highlights!

By Yona Torres, New Frontier Data Contributing Editor “This is the year that CBD arrived,” proclaimed Sean Murphy, Director of Hemp Analytics for New Frontier Data. It was Standing Room Only at the Natural Products Expo West 2018,where CBD took center stage stemming from new products-excitement. Much of the action in CBD has been from […]
Read more

Jeff Sessions Rescinds the Cole Memo, Raising Concerns With Tough Talk but No More Resources to Prosecute

By J.J. McCoy, Senior Managing Editor for New Frontier Data What We Have Learned: Two months after rescinding the Cole Memo, Jeff Sessions said that federal law enforcement lacked resources to really change its policy. In a three-paragraph memo released in January, U.S. Attorney General Jeff Sessions rescinded several Obama-era directives which since 2013 had discouraged […]
Read more

WHO Research About CBDs: They Are A-OK

By J.J. McCoy, Senior Managing Editor for New Frontier Data What We Have Learned: The World Health Organization (WHO) essentially called out the rationale behind the U.S. federal government’s listing cannabis as a Schedule I controlled substance. Newly published findings from the World Health Organization (WHO) about the medicinal benefits of cannabidiol (CBD) fall in direct […]
Read more

What are the Upsides for Cannabis Businesses Under the Final Tax Reforms?

By Selvan Boominathan, JD, LLM, of CohnReznick What We Have Learned: The QBI deduction (with lower rates across the board, and capital expenditure incentives) should be a boon to the industry at large. The Tax Cuts and Jobs Act (TCJA) has become the law of the land, and yet, still no relief for cannabis businesses […]
Read more

Where Do Things Look to Stand with the Rohrabacher-Blumenauer Amendment?

By J.J. McCoy, Senior Managing Editor for New Frontier Data What We Have Learned: As Congress keeps kicking continuing budget resolutions down the calendar, there remain steps for operators to toward self-protection. In what has become a de facto annual event on Capitol Hill (where a version was first proposed in 2001, finally passed in 2014, […]
Read more

Will New York Finally Get Serious About Cannabis?

By J.J. McCoy, Senior Managing Editor for New Frontier Data What We Have Learned: While Governor Cuomo once dragged his feet about New York’s cannabis market, he started stepping up to the plate in 2018. It has been some time coming for New York’s state of mind to open up to the medical and market potentials […]
Read more

How to Evaluate Valuations in the Cannabis Marketplace

By Andrew Lines, MAI, Principal What We Have Learned: In valuing the business operations of companies in the cannabis industry, risk is a significant factor that can dampen even the most optimistic outlook and projections. Valuations within the growing cannabis industry don’t always seem to be consistent with operator or investor expectations; this can be […]
Read more
Top